

MINI REVIEW



Endothelial dysfunction: A vital element in cardiovascular disease and beyond

Amisha Biswal

Department of Biotechnology, MITS School of Biotechnology, Bhubaneswar, Odisha, India

ABSTRACT

Endothelial dysfunction is progressively acknowledged as a vital pathophysiological occurrence in the onset of cardiovascular diseases (CVD) and other chronic ailments. It is marked by a dysfunction in the endothelium's capacity to sustain vascular homeostasis, resulting in modified vascular tone, heightened inflammation, and conditions favorable to thrombosis. Endothelial cells that coat the blood vessels are crucial in managing vascular function, and their dysfunction can be caused by various risk factors including hypertension, hyperlipidemia, smoking, diabetes, and obesity. This article examines the processes that contribute to endothelial dysfunction, its involvement in the development of cardiovascular disease, and its connection to other illnesses. Additionally, it explores possible therapeutic approaches focused on reestablishing endothelial function, emphasizing lifestyle changes, medication options, and new treatment methods.

KEYWORDS

Endothelial dysfunction;
Cardiovascular disease;
Hyperglycemia; Risk factors;
Therapeutic strategies

ARTICLE HISTORY

Received 6 February 2025;
Revised 21 February 2025;
Accepted 28 February 2025

Introduction

Endothelial dysfunction describes the compromised capability of the endothelium to control vascular tone and uphold homeostasis. This process is crucial in the development of numerous cardiovascular diseases, such as atherosclerosis, hypertension, and heart failure. The endothelium plays a complex role in vascular health by regulating blood flow, coagulation, and inflammatory processes [1]. A healthy endothelium generates substances like nitric oxide, aiding vasodilation and minimizing vascular inflammation. Nevertheless, in pathological situations, this equilibrium is disturbed, resulting in vasoconstriction, inflammation, thrombosis, and the development of atherosclerotic plaques [2,3].

Endothelial dysfunction is viewed as an initial occurrence in the progression of cardiovascular diseases and can frequently be reversed in its early phases. Nevertheless, if not addressed, it may advance to more serious issues like atherosclerosis, coronary artery disease, and potentially stroke. This article examines the molecular and cellular processes that cause endothelial dysfunction, its contribution to cardiovascular pathophysiology, and possible strategies for prevention and treatment [4].

Mechanisms of Endothelial Dysfunction

Endothelial dysfunction mainly arises from a mix of genetic factors, environmental influences, and personal lifestyle decisions. Grasping the molecular mechanisms related to Endothelial dysfunction can provide insights into preventive and treatment approaches [5].

Impaired nitric oxide production

A key characteristic of endothelial dysfunction is the decreased availability of nitric oxide. NO serves as an essential mediator of vasodilation, and its synthesis is predominantly controlled by the endothelial nitric oxide synthase (eNOS) enzyme [6]. Under typical circumstances, it facilitates the relaxation of vascular

smooth muscle, lowers blood pressure, and enhances blood circulation. Nonetheless, elements like oxidative stress, inflammation, and high blood sugar can hinder eNOS function, resulting in lower NO production and, hence, endothelial dysfunction [7,8].

Oxidative stress

Oxidative stress, resulting from an abundance of reactive oxygen species (ROS), is another significant factor in endothelial dysfunction. ROS, such as superoxide and hydrogen peroxide, can deactivate NO by creating peroxynitrite, a highly reactive compound that causes additional harm to endothelial cells. Oxidative stress may be induced by risk factors including smoking, diets high in fat, inactive lifestyles, and poorly managed diabetes [9-11].

Inflammation

Chronic low-level inflammation is strongly associated with endothelial dysfunction. Inflammatory cytokines like tumor necrosis factor-alpha (TNF- α) and interleukins can stimulate the endothelium and enhance the expression of adhesion molecules, aiding in the recruitment of inflammatory cells to the vascular wall [12]. This worsens endothelial damage and aids in the progression of atherosclerosis. Additionally, inflammation hinders the capacity of endothelial cells to generate NO, worsening the dysfunction [13,14].

Lipid accumulation and dyslipidemia

Increased amounts of low-density lipoprotein (LDL) cholesterol, particularly oxidized LDL, may harm the endothelium. Oxidized LDL triggers apoptosis in endothelial cells, raises vascular permeability, and amplifies the inflammatory response. Dyslipidemia, defined by low HDL (high-density lipoprotein) and high LDL levels, intensifies endothelial dysfunction and encourages the development of atherosclerotic plaques [15].

*Correspondence: Ms. Amisha Biswal, Department of Biotechnology, MITS School of Biotechnology, Bhubaneswar, Odisha, India, e-mail: biswalamisha316@gmail.com

© 2025 The Author(s). Published by Reseapro Journals. This is an Open Access article distributed under the terms of the Creative Commons Attribution License

(<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Insulin resistance and hyperglycemia

Insulin resistance, an early indicator of type 2 diabetes, is strongly associated with endothelial dysfunction [16]. Insulin resistance hinders the endothelial cells' response to insulin and reduces NO production. High blood sugar levels may also harm endothelial cells directly by enhancing the production of advanced glycation end-products (AGEs), which lead to oxidative stress and inflammation (Figure 1) [17,18].




Figure 1. Flow chart showing the mechanisms of endothelial dysfunction.

Risk Factors for Endothelial Dysfunction

Several modifiable and non-modifiable risk factors lead to endothelial dysfunction. Grasping these risk factors is crucial for preventing and handling ED and its related conditions [19,20].

Hypertension

Persistent high blood pressure exerts mechanical strain on the endothelial cells, resulting in damage to the endothelium. With time, hypertension may decrease the bioavailability of NO, encourage oxidative stress, and initiate inflammatory pathways, all of which lead to endothelial dysfunction [18].

Smoking

Cigarette smoking is a significant contributor to endothelial dysfunction. Smoking creates oxidative stress, enhances the generation of pro-inflammatory cytokines, and decreases NO availability [5]. The joint influence of these elements results in compromised endothelial function and heightened vascular stiffness.

Obesity

Obesity is linked to higher levels of pro-inflammatory cytokines, modified lipid profiles, and insulin resistance. These elements lead to endothelial dysfunction and elevate the risk of cardiovascular conditions. Additionally, adipose tissue emits free fatty acids that can directly disrupt endothelial function [19].

Sedentary lifestyle

Inadequate physical activity is closely linked to endothelial dysfunction. Consistent physical activity boosts endothelial function by increasing nitric oxide production, lowering oxidative stress, and enhancing lipid profiles. On the other hand, lack of physical activity leads to the emergence of risk

factors like obesity, high blood pressure, and dyslipidemia [20].

Endothelial Dysfunction and Cardiovascular Disease

Endothelial dysfunction plays a vital role in the progression of numerous cardiovascular diseases, such as atherosclerosis, coronary artery disease (CAD), and heart failure.

Atherosclerosis

Atherosclerosis is a long-term inflammatory condition marked by the buildup of lipids and fibrous material in the arterial wall. Endothelial dysfunction is crucial in the onset and advancement of atherosclerosis. It triggers the inflammatory response, boosts endothelium permeability to lipoproteins, and causes plaque formation that constricts blood vessels and limits blood flow [21].

Coronary artery disease (CAD)

In CAD, endothelial dysfunction plays a role in creating coronary plaques, leading to the narrowing or total obstruction of the coronary arteries. This decreases oxygen supply to the heart muscle and raises the likelihood of myocardial infarction (heart attack). ED also disrupts coronary vasodilation, causing irregular blood flow and ischemia [22].

Heart failure

In heart failure, endothelial dysfunction leads to compromised vascular function and fluid retention. This worsens symptoms like swelling and difficulty breathing. Moreover, in heart failure patients, endothelial dysfunction correlates with a negative prognosis since it exacerbates vascular resistance and constrains the heart's efficiency in pumping blood [10,21,22].

Therapeutic Approaches for Endothelial Dysfunction

Restoring endothelial function is crucial in preventing and managing cardiovascular diseases. Several therapeutic strategies have been explored to reverse endothelial dysfunction [15,22].

Lifestyle interventions

The foundation of addressing endothelial dysfunction consists of changes in lifestyle. This comprises of consistent physical activity boosts NO production, decreases oxidative stress, and enhances endothelial function [4,9]. A heart-friendly diet abundant in fruits, vegetables, whole grains, and nutritious fats can lower oxidative stress and inflammation. Stopping smoking decreases oxidative harm and enhances endothelial performance. Keeping a healthy weight lessens inflammation and enhances insulin sensitivity, which both support endothelial performance [23].

Pharmacological treatments

Various medications are available for addressing endothelial dysfunction, such as statins, often employed to reduce cholesterol, and additionally possess protective effects on the endothelium [7]. They increase NO production, lessen inflammation, and promote endothelial function. ACE Inhibitors and Angiotensin Receptor Blockers (ARBs): These drugs aid in lowering blood pressure and enhancing endothelial function by inhibiting the effects of angiotensin II, a strong vasoconstrictor [24]. Antioxidant treatment, such as vitamins C and E, may lower oxidative stress and enhance endothelial function, but evidence supporting their extensive use is scarce [6].

Emerging therapies

Several innovative treatments are being investigated for endothelial dysfunction treatments based on genes that seek to reinstate eNOS expression or boost NO production in endothelial cells. Therapies utilizing stem cells could provide possibilities for repairing or regenerating harmed endothelial cells (Table 1) [2,25].

Table 1. Risk factors and their impact on endothelial dysfunction.

Risk factor	Mechanism of impact	Effect on endothelium
Hypertension	Increased mechanical stress on endothelial cells	Reduced NO production, increased inflammation
Smoking	Increased oxidative stress, reduced NO bioavailability	Endothelial damage, increased thrombosis risk
Obesity	Inflammation, altered lipid profile, insulin resistance	Reduced NO production, impaired function
Diabetes	Hyperglycemia, AGEs formation	Increased oxidative stress, endothelial injury
Physical inactivity	Reduced NO production, increased oxidative stress	Impaired endothelial function

Conclusions

Endothelial dysfunction is a vital pathological mechanism that contributes to the onset of cardiovascular diseases and various chronic ailments. It is affected by numerous risk factors, such as hypertension, smoking, obesity, and diabetes. Timely identification and action are essential, as lifestyle modifications and medical therapies can frequently reverse endothelial dysfunction. A thorough strategy for addressing endothelial dysfunction, emphasizing lifestyle changes and specific treatments, is crucial for enhancing cardiovascular well-being and averting disease progression. As we deepen our comprehension of the molecular mechanisms underlying ED, innovative therapeutic approaches could provide optimism for improved management and potential reversal of endothelial dysfunction.

Disclosure statement

The authors declare that they have no competing interests.

References

- Gimbrone Jr MA, García-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. *Circ Res*. 2016;118(4):620-636. <https://doi.org/10.1161/CIRCRESAHA.115.306301>
- Cannon III RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. *Clin Chem*. 1998;44(8):1809-1819. <https://doi.org/10.1093/clinchem/44.8.1809>
- Tousoulis D, Kampoli AM, Tentolouris NPC, Stefanadis C. The role of nitric oxide on endothelial function. *Curr Vasc Pharmacol*. 2012;10(1):4-18. <https://doi.org/10.2174/157016112798829760>
- Naderi-Meshkin H, Setyaningsih WA. Endothelial cell dysfunction: onset, progression, and consequences. *Front Biosci*. 2024;29(6):223. <https://doi.org/10.31083/j.fbl2906223>
- Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, et al. Targeting vascular (endothelial) dysfunction. *Br J Pharmacol*. 2017;174(12):1591-1619. <https://doi.org/10.1111/bph.13517>

- Bermudez V, Bermudez F, Acosta G, Acosta A, Anez J, Andara C, et al. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition. *Am J Ther*. 2008;326-333p. <https://doi.org/10.1097/MJT.0b013e318160beda>
- Goligorsky MS, Gross SS. The ins and outs of endothelial dysfunction: much ado about NO-thing. *Drug News Perspect*. 2001;14(3):133-142. Available at <https://pubmed.ncbi.nlm.nih.gov/12819819/>
- Desjardins F, Balligand JL. Nitric oxide-dependent endothelial function and cardiovascular disease. *Acta Clin Belg*. 2006;61(6):326-334. <https://doi.org/10.1179/acb.2006.052>
- Ogita H, Liao JK. Endothelial function and oxidative stress. *Endothelium*. 2004;11(2):123-132. <https://doi.org/10.1080/10623320490482664>
- Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. *Vasc Pharmacol*. 2018;100:1-9. <https://doi.org/10.1016/j.vph.2017.05.005>
- Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. *Ann Med*. 2008;40(3):180-196. <https://doi.org/10.1080/07853890701854702>
- Boulanger CM. Endothelium. Arteriosclerosis, thrombosis, and vascular biology. 2016;36(4):26-31. <https://doi.org/10.1161/ATVBAHA.116.306940>
- Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis C, et al. Inflammatory mechanisms contributing to endothelial dysfunction. *Biomedicines*. 2021;9(7):781. <https://doi.org/10.3390/biomedicines9070781>
- Dri E, Lampas E, Lazaros G, Lazarou E, Theofilis P, Tsioufis C, et al. Inflammatory mediators of endothelial dysfunction. *Life*. 2023;13(6):1420. <https://doi.org/10.3390/life13061420>
- Mundi S, Massaro M, Scoditti E, Carluccio MA, Van Hinsbergh VW, Iruela-Arispe ML, et al. Endothelial permeability, LDL deposition, and cardiovascular risk factors—A review. *Cardiovasc Res*. 2018;114(1):35-52. <https://doi.org/10.1093/cvr/cvx226>
- Del Turco S, Gaggini M, Daniele G, Basta G, Folli F, Sicari R, et al. Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. *Curr Pharm Des*. 2013;19(13): 2420-2431. Available at <https://pubmed.ncbi.nlm.nih.gov/23173591/>
- Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. *Diabet Med*. 2003;20(4):255-268. <https://doi.org/10.1046/j.1464-5491.2003.00869.x>
- DeLay KJ, Haney N, Hellstrom WJ. Modifying risk factors in the management of erectile dysfunction: a review. *World J Mens Health*. 2016;34(2):89-100. <http://dx.doi.org/10.5534/wjmh.2016.34.2.89>
- Glina S, Sharlip ID, Hellstrom WJ. Modifying risk factors to prevent and treat erectile dysfunction. *J sexual med*. 2013;10(1): 115-119. <https://doi.org/10.1111/j.1743-6109.2012.02816.x>
- Müller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. *Curr Opin Urol*. 2006;16(6):435-443. <https://doi.org/10.1097/01.mou.0000250284.83108.a6>
- Steyers III CM, Miller Jr FJ. Endothelial dysfunction in chronic inflammatory diseases. *Int J Mol Sci*. 2014;15(7):11324-11349. <https://doi.org/10.3390/ijms150711324>
- Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes Jr DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation*. 2000;101(9):948-954. <https://doi.org/10.1161/01.CIR.101.9.948>
- Deshpande DD, Janero DR, Amiji MM. Therapeutic strategies for endothelial dysfunction. *Expert Opin Biol Ther*. 2011;11(12): 1637-1654. <https://doi.org/10.1517/14712598.2011.625007>
- Silva IV, de Figueiredo RC, Rios DR. Effect of different classes of antihypertensive drugs on endothelial function and inflammation. *Int J Mol Sci*. 2019;20(14):3458. <https://doi.org/10.3390/ijms20143458>
- Poredoš P. Endothelial dysfunction and cardiovascular disease. Pathophysiology of haemostasis and thrombosis. 2002;32(5-6):274-277. Available at <https://pubmed.ncbi.nlm.nih.gov/13679656/>